RBC Capital Maintains Outperform on Design Therapeutics, Raises Price Target to $14
Design Therapeutics, Inc.
Design Therapeutics, Inc. DSGN | 0.00 |
RBC Capital analyst Leonid Timashev maintains Design Therapeutics (NASDAQ:
DSGN) with a Outperform and raises the price target from $13 to $14.
